Most IVIg-mobilized CD19⁺CD27^high cells are immature.

(A) Representative analyses of circulating and bone marrow CD19⁺CD27^high cells in a GBS patient 7 days after IVIg infusion and in a healthy bone marrow donor. (B) Control mature medullary CD19⁺CD27^high plasma cells (as identified in panel A, right) were CXCR4^highCD138^highHLA-DR^low (gray line). Circulating IVIg-mobilized CD19⁺CD27^high plasma cells were CXCR4^lowCD138^lowHLA-DR^high (solid line). Isotype controls were presented (dotted line). (C) Balance between immature (HLA-DR^high) and mature (HLA-DR^low) plasma cells (PCs) in IVIg-treated patients 7 days after treatment. GBS (disability grade 3 or more, n = 40) and CIDP (n = 14) patients received IVIg only, whereas MG (n = 7) and IM (n = 6) patients received IVIg and steroids. Data are mean ± s.e.m. Comparisons of indicated mean values were performed by use of Mann-Whitney U test.